<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413021</url>
  </required_header>
  <id_info>
    <org_study_id>78001</org_study_id>
    <nct_id>NCT02413021</nct_id>
  </id_info>
  <brief_title>The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens</brief_title>
  <official_title>Phase 1 Study of Deferasirox in Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether deferasirox is effective in the treatment
      of acute lymphatic leukemia (ALL) and acute Myeloid leukemia (AML).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many studies have demonstrated that Iron is essential for the metabolism, cell cycle
      regulation and metastasis in different cancer cell lines. It is also believed that Iron
      concentration will increase in cancer cells by enhancing expression of TFR-1 receptors and in
      case of receptor saturation, non-receptor-mediated pinocytosis would be a significant pathway
      for more iron intake. Iron deficiency may lead to increase P 53 which consequently will stop
      cell mitosis in G1-S state. It also increases expression of N-myc down-regulated gene 1 which
      can suppress metastasis in cancer. It has been suggested that Iron chelators may decrease
      leukemic tumor growth in animal models of acute myeloid leukemia (AML). Some other case
      studies demonstrated the role of Iron chelators in relapse and/or refractory AML. Finally a
      phase 1 clinical study is undertaken for evaluate the role of Tiapine and cytarabine for
      adult AML and high-risk myelodysplastic syndrome. So in this study the investigators try to
      evaluate the role of iron chelating agent (deferasirox) for patients with acute lymphatic
      leukemia (ALL) and AML patients who cannot be treated with standard chemotherapy regimes .
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete Remission</measure>
    <time_frame>first month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial Remission</measure>
    <time_frame>up to four weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>deferasirox + cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>deferasirox + cytarabine group will receive oral deferasirox at 20 mg/kg per day and cytarabine at20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cytarabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cytarabine group will receive just cytarabine at 20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>20 mg/m^2 , SC, two times a day for 10 days every 30 days for 1 cycle</description>
    <arm_group_label>deferasirox + cytarabine</arm_group_label>
    <arm_group_label>cytarabine</arm_group_label>
    <other_name>Cytosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox</intervention_name>
    <description>20 mg/kg ,oral, per day</description>
    <arm_group_label>deferasirox + cytarabine</arm_group_label>
    <other_name>osveral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients with acute leukemia (myeloid or lymphoblastic) who do not receive the standard
        chemotherapy regimens for treatment; because of the following reasons:

          1. age &gt; 65

          2. existence of another illness, such as heart failure (EF&gt; 40)

        2. Ferritin &lt; 500 μg / l

        3. Not existence of other co morbidity

        4. GFR &gt; 40

        Exclusion Criteria:

          1. GFR &lt; 40

          2. Control group become iron overloaded (Ferritin &gt; 500 μg /l)

          3. Incidence of any severe gastrointestinal symptoms (Mucositis, Enterocolitis,
             Typhlitis, Nausea, Diarrhea)

          4. Not willing to continue treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valiollah Mehrzad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seyyed-alshohada hospital of Isfahan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shaghayegh Haghjoo Javanmard, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Applied Physiology Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahnaz Danesh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seyyed-alshohada hospital of Isfahan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alireza Eishi, Med student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Applied Physiology Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahnaz Danesh, MD</last_name>
    <phone>00983132350210</phone>
    <email>takabgh@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alireza Eishi, Med student</last_name>
    <phone>00983137922295</phone>
    <email>alireza.eishi@yahoo.com</email>
  </overall_contact_backup>
  <link>
    <url>http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm183861.htm</url>
    <description>Deferasirox Information</description>
  </link>
  <reference>
    <citation>Heath JL, Weiss JM, Lavau CP, Wechsler DS. Iron deprivation in cancer--potential therapeutic implications. Nutrients. 2013 Jul 24;5(8):2836-59. doi: 10.3390/nu5082836. Review.</citation>
    <PMID>23887041</PMID>
  </reference>
  <reference>
    <citation>Paubelle E, Zylbersztejn F, Alkhaeir S, Suarez F, Callens C, Dussiot M, Isnard F, Rubio MT, Damaj G, Gorin NC, Marolleau JP, Monteiro RC, Moura IC, Hermine O. Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure. PLoS One. 2013 Jun 20;8(6):e65998. doi: 10.1371/journal.pone.0065998. Print 2013.</citation>
    <PMID>23840388</PMID>
  </reference>
  <reference>
    <citation>Fukushima T, Kawabata H, Nakamura T, Iwao H, Nakajima A, Miki M, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Hirose Y, Umehara H. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res. 2011 May;31(5):1741-4.</citation>
    <PMID>21617233</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isfahan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Golnaz Vaseghi</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Acute Lymphoid Leukemia</keyword>
  <keyword>deferasirox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

